Freenome said today that it has raised $290 million from Roche to advance its cancer early detection platform, which uses a routine blood draw.
The South San Francisco, California–based company has raised more than $1.1 billion since its founding in 2014.
Get the full story on our sister site MassDevice.
Filed Under: Oncology
Tell Us What You Think!
You must be logged in to post a comment.